| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(02)08094-7 |
| P698 | PubMed publication ID | 11937183 |
| P50 | author | Willy Rozenbaum | Q2945169 |
| Hubert Vidal | Q33112025 | ||
| P2093 | author name string | Martine Laville | |
| Corinne Vigouroux | |||
| Jacqueline Capeau | |||
| Martine Caron | |||
| Mustapha Maachi | |||
| Martine Auclair | |||
| Philippe Levan | |||
| Pierre Marie Girard | |||
| Jacqueline Luboinski | |||
| Jean Philippe Bastard | |||
| Véronique Jan | |||
| P2860 | cites work | Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells | Q24561820 |
| Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice | Q24620943 | ||
| Metabolic effects of indinavir in healthy HIV-seronegative men | Q28366603 | ||
| Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes | Q33957444 | ||
| Adverse effects of antiretroviral therapy | Q34071132 | ||
| Lipodystrophies | Q34110938 | ||
| Mitochondrial toxicity hypothesis for lipoatrophy: a refutation | Q34198112 | ||
| Metabolic complications associated with antiretroviral therapy | Q34305866 | ||
| Life without white fat: a transgenic mouse | Q35210661 | ||
| Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy | Q35210714 | ||
| An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses | Q36638199 | ||
| Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism | Q39446637 | ||
| Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors | Q40851323 | ||
| Promoter analysis of the mouse sterol regulatory element-binding protein-1c gene | Q40864894 | ||
| TNF-alpha inhibits 3T3-L1 adipocyte differentiation without downregulating the expression of C/EBPbeta and delta | Q42827195 | ||
| The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance | Q42828632 | ||
| Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. | Q43618955 | ||
| Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway | Q43690470 | ||
| HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus | Q43730373 | ||
| A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia | Q43766799 | ||
| Autologous fat transplantation | Q44203104 | ||
| Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study | Q44820677 | ||
| Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters | Q45783344 | ||
| Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. | Q51554572 | ||
| Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. | Q51556296 | ||
| Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. | Q54059188 | ||
| The use of the reverse transcription-competitive polymerase chain reaction to investigate the in vivo regulation of gene expression in small tissue samples | Q73123144 | ||
| Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy | Q73187597 | ||
| Tumor necrosis factor-alpha induces apoptosis of human adipose cells | Q73929085 | ||
| Adipose tissue as an endocrine and paracrine organ | Q77758550 | ||
| P433 | issue | 9311 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adipocyte | Q357519 |
| preproinsulin | Q7240673 | ||
| insulin resistance | Q1053470 | ||
| P304 | page(s) | 1026-1031 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance | |
| P478 | volume | 359 |
| Q37448602 | A pilot study of sampling subcutaneous adipose tissue to examine biomarkers of cancer risk |
| Q36292303 | A review of the aetiology of dyslipidaemia and hyperlipidaemia in patients with HIV. |
| Q35689443 | Adipocyte, adipose tissue, and infectious disease |
| Q42834514 | Adiponectin Ameliorates Dyslipidemia Induced by the Human Immunodeficiency Virus Protease Inhibitor Ritonavir in Mice |
| Q40038736 | Adipose Tissue in HIV Infection |
| Q36612337 | Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice |
| Q37187518 | Adipose tissue and immune function: a review of evidence relevant to HIV infection |
| Q58642121 | Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy |
| Q59326204 | Adipose tissue lipin expression levels distinguish HIV patients with and without lipodystrophy |
| Q46825352 | Adverse effects of antiretroviral treatments |
| Q35025568 | Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy |
| Q36049795 | Androgen effects on adipose tissue architecture and function in nonhuman primates. |
| Q34911321 | Anti-HIV drugs for cancer therapeutics: back to the future? |
| Q36933854 | Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost? |
| Q37033675 | Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways |
| Q35136008 | Apoptosis as an HIV strategy to escape immune attack |
| Q30248286 | Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy |
| Q43508252 | Blepharoptosis and external ophthalmoplegia associated with long-term antiretroviral therapy |
| Q37604169 | Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART |
| Q36206201 | Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors |
| Q37341305 | Body-fat abnormalities in patients with HIV: progress and challenges |
| Q53851252 | British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). |
| Q34033578 | C/EBP transcription factors regulate SREBP1c gene expression during adipogenesis |
| Q61835542 | CIVD, choc septique : Diagnostic biologique et traitements innovants |
| Q36651656 | Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy |
| Q36011828 | Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. |
| Q42203659 | Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients |
| Q36937853 | Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy |
| Q58168449 | Circulating sex hormones and gene expression of subcutaneous adipose tissue oestrogen and alpha-adrenergic receptors in HIV-lipodystrophy: implications for fat distribution |
| Q28246346 | Clinical review#: Lipodystrophies: genetic and acquired body fat disorders |
| Q36951689 | Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro |
| Q35400307 | Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy |
| Q45395353 | Determinants of endothelial function in human immunodeficiency virus infection: a complex interplay among therapy, disease, and host factors |
| Q59356122 | Differential contribution of chronic binge alcohol and antiretroviral therapy to metabolic dysregulation in SIV-infected male macaques |
| Q35076628 | Differential interactions of antiretroviral agents with LXR, ER and GR nuclear receptors: potential contributing factors to adverse events |
| Q34596899 | Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients. |
| Q38284300 | Diverse lamin-dependent mechanisms interact to control chromatin dynamics. Focus on laminopathies |
| Q36392681 | Drug-induced metabolic syndrome |
| Q37845703 | Dyslipidemia in HIV-infected individuals |
| Q33787957 | Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation |
| Q35053466 | Effects of HIV protease inhibitor therapy on lipid metabolism |
| Q33918414 | Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients |
| Q34312147 | Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis |
| Q38130907 | Endocrine and metabolic abnormalities among HIV-infected patients: a current review |
| Q38155007 | Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies |
| Q36265235 | Fat in the liver and insulin resistance |
| Q34503338 | Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue |
| Q35557342 | Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy |
| Q96576975 | HIV and antiretroviral therapy-related fat alterations |
| Q35975980 | HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue. |
| Q40252395 | HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism |
| Q34534986 | HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study |
| Q28082749 | HIV protease inhibitors: a review of molecular selectivity and toxicity |
| Q41369732 | HIV-1 infection and the PPARγ-dependent control of adipose tissue physiology |
| Q79328905 | HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy |
| Q36171069 | HIV-associated lipodystrophy syndrome: A review of clinical aspects |
| Q39015233 | HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives? |
| Q35769323 | HIV-related lipodystrophy and related factors |
| Q37238258 | Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons |
| Q79254756 | How bad is HAART for the HEART? |
| Q36745558 | Human adipose dynamics and metabolic health |
| Q36445636 | Human genetic variability and HIV treatment response |
| Q45138632 | Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines |
| Q35073490 | Human immunodeficiency virus therapeutics and pharmacogenomics |
| Q53542805 | Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. |
| Q35696547 | Hyperlipidemia in children with HIV infection: an emerging problem |
| Q35176441 | Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution |
| Q35567828 | Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs |
| Q34205448 | Impact of randomized antiretroviral therapy initiation on glucose metabolism |
| Q39771275 | Impact of stimulatory pathways on adipogenesis and HIV-therapy associated lipoatrophy |
| Q36870336 | Impaired expression of mitochondrial and adipogenic genes in adipose tissue from a patient with acquired partial lipodystrophy (Barraquer-Simons syndrome): a case report |
| Q40578427 | Improved adipose tissue function with initiation of protease inhibitor-only ART. |
| Q46908306 | In treatment-naïve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100. |
| Q38346020 | In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. |
| Q44522392 | Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels |
| Q51472716 | Increased expression of the macrophage markers and of 11beta-HSD-1 in subcutaneous adipose tissue, but not in cultured monocyte-derived macrophages, is associated with liver fat in human obesity. |
| Q44609997 | Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy |
| Q37161855 | Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women |
| Q90602763 | Inflammation and Metabolic Complications in HIV |
| Q39940257 | Inflammation in subcutaneous adipose tissue: relationship to adipose cell size. |
| Q35087005 | Insulin resistance in HIV-related lipodystrophy |
| Q38108736 | Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS. |
| Q35110681 | Is oxygen a key factor in the lipodystrophy phenotype? |
| Q35239494 | Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications |
| Q46596340 | Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive |
| Q31143771 | Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. |
| Q36891873 | Lipodystrophy in HIV 1-infected patients: lessons for obesity research |
| Q37634512 | Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity |
| Q40903070 | Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice |
| Q44763937 | Managing HIV lipoatrophy |
| Q39670294 | Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors |
| Q45099760 | Metabolic alterations in HIV-associated lipodystrophy syndrome |
| Q35592375 | Metabolic complications associated with HIV protease inhibitor therapy |
| Q36593775 | Mitochondrial DNA content, an inaccurate biomarker of mitochondrial alteration in human immunodeficiency virus-related lipodystrophy. |
| Q33558933 | Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors |
| Q36880847 | Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments |
| Q35250665 | Molecular Mechanisms for Altered Glucose Homeostasis in HIV Infection |
| Q37887885 | Molecular mechanisms for insulin resistance in treated HIV-infection |
| Q35557229 | New and emerging agents in the management of lipodystrophy in HIV-infected patients |
| Q44396314 | No Relationship BetweenTNF-αGenetic Variants and Combination Antiretroviral Therapy-Related Lipodystrophy Syndrome in HIV Type 1-Infected Patients: A Case-Control Study and a Meta-Analysis |
| Q44763941 | No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. |
| Q38105267 | Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS. |
| Q91529171 | Peroxisome Proliferator-Activated Receptor-gamma agonists exhibit anti-inflammatory and antiviral effects in an EcoHIV mouse model |
| Q37208433 | Peroxisome proliferator-activated receptor-gamma activation suppresses HIV-1 replication in an animal model of encephalitis. |
| Q57790349 | Peroxisome proliferator-activated receptor-γ and lipodystrophy |
| Q28202926 | Peroxisome proliferator-activated receptors in cutaneous biology |
| Q37523821 | Phase I study of nelfinavir in liposarcoma |
| Q36509694 | Physical fitness in children infected with the human immunodeficiency virus: associations with highly active antiretroviral therapy |
| Q35187774 | Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria |
| Q93194459 | Pseudoacromegaly |
| Q35167541 | RNA interference: potentials for the prevention of HIV infections and the challenges ahead |
| Q30481446 | Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy |
| Q45354625 | Relationship of fat distribution with adipokines in patients with acquired immunodeficiency virus infection. |
| Q37192579 | Repositioning HIV protease inhibitors as cancer therapeutics |
| Q40619439 | Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation |
| Q92537912 | Specific Biological Features of Adipose Tissue, and Their Impact on HIV Persistence |
| Q35129349 | Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals |
| Q54215275 | The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies. |
| Q35676408 | The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities |
| Q36993971 | The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients |
| Q44482690 | The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation. |
| Q37405140 | The impact of pharmacogenetics on HIV therapy |
| Q37738331 | The spectrum of atherosclerotic coronary artery disease in HIV patients |
| Q36914988 | Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy |
| Q36841072 | Thiazolidinediones in dermatology |
| Q36505451 | Thymidine analogues suppress autophagy and adipogenesis in cultured adipocytes |
| Q81653120 | To kill or be killed: how HIV exhausts the immune system |
| Q36544924 | Toxic metabolic syndrome associated with HAART. |
| Q35194751 | Toxicity of antiretroviral therapy and implications for drug development |
| Q42807673 | Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis |
| Q42170740 | Ultrasonographic measurement of intra-abdominal fat thickness in HIV-infected patients treated or not with antiretroviral drugs and its correlation to lipid and glycemic profiles |
| Q35833512 | Update on HIV lipodystrophy |
| Q79183185 | [Adverse effects of antiretroviral therapy. Aspects of pathogenesis] |
| Q81573392 | [Antiretroviral treatments-related lipodystrophy syndrome: clinico-pathological findings] |
Search more.